dc.contributor.author |
Auclin, Edouard |
dc.contributor.author |
André, Thierry |
dc.contributor.author |
Taieb, Julien |
dc.contributor.author |
Banzi, Maria |
dc.contributor.author |
Van Laethem, Jean-Luc |
dc.contributor.author |
Tabernero, Josep |
dc.contributor.author |
Hickish, Tamas |
dc.contributor.author |
de Gramont, Aimery |
dc.contributor.author |
Vernerey, Dewi |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2019 |
dc.identifier |
https://ddd.uab.cat/record/238806 |
dc.identifier |
urn:10.1038/s41416-019-0521-7 |
dc.identifier |
urn:oai:ddd.uab.cat:238806 |
dc.identifier |
urn:pmcid:PMC6738041 |
dc.identifier |
urn:pmc-uid:6738041 |
dc.identifier |
urn:pmid:31296923 |
dc.identifier |
urn:articleid:15321827v121p312 |
dc.identifier |
urn:scopus_id:85068769669 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:6738041 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
British Journal of Cancer ; Vol. 121 (july 2019), p. 312-317 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Colorectal cancer |
dc.subject |
Colon cancer |
dc.title |
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial |
dc.type |
Article |
dc.description.abstract |
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2.35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. Prognostic and predictive values of post-operative CEA in patients with stage II CC were evaluated with Kaplan-Meier survival curves and Cox model with interaction terms. Disease-free survival (DFS) and overall survival (OS) were estimated. Among 899 stage II CC patients, post-operative CEA was available in 867 (96.4%); and 434 (48.65%) had a high-risk stage II disease. The 3-year DFS rate was 88.5% and 78.7% in the ≤ 2.35 ng/mL and > 2.35 ng/mL group, respectively (P = 0.006). Use of oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA > 2.35 ng/ml (interaction term P = 0.09 and 0.03 for DFS and OS). CEA is a strong prognostic factor for DFS and OS in stage II CC. In the MOSAIC trial, only high-risk stage II CC patients with post-operative CEA > 2.35 ng/mL benefited from the addition of oxaliplatin to LV5FU2. NCT00275210 (January 11, 2006). |